首页> 外文期刊>Oncogene >The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
【24h】

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

机译:FGFR4 Y367C突变体是MDA-MB453乳腺癌细胞中的主要致癌基因

获取原文
           

摘要

Mutational analysis of oncogenes is critical for our understanding of cancer development. Oncogenome screening has identified a fibroblast growth factor receptor 4 (FGFR4) Y367C mutation in the human breast cancer cell line MDA-MB453. Here, we investigate the consequence of this missense mutation in cancer cells. We show that MDA-MB453 cells harbouring the mutation are insensitive to FGFR4-specific ligand stimulation or inhibition with an antagonistic antibody. Furthermore, the FGFR4 mutant elicits constitutive phosphorylation leading to an activation of the mitogen-activated protein kinase cascade as shown by an enhanced Erk1/2 phosphorylation. Cloning and ectopic expression of the FGFR4 Y367C mutant in HEK293 cells revealed high pErk levels and enhanced cell proliferation. Based on these findings, we propose that FGFR4 may be a driver of tumour growth, particularly when highly expressed or stabilized and constitutively activated through genetic alterations. As such, FGFR4 presents an option for further mutational screening in tumours and is an attractive cancer target with the therapeutic potential.
机译:癌基因的突变分析对于我们对癌症发展的了解至关重要。癌基因组筛选已鉴定出人乳腺癌细胞系MDA-MB453中的成纤维细胞生长因子受体4(FGFR4)Y367C突变。在这里,我们调查这种错义突变在癌细胞中的后果。我们显示,具有突变的MDA-MB453细胞对FGFR4特异性配体刺激或拮抗性抗体不敏感。此外,FGFR4突变体引起组成型磷酸化,导致丝裂原活化的蛋白激酶级联反应的激活,如增强的Erk1 / 2磷酸化所示。 FGFR4 Y367C突变体在HEK293细胞中的克隆和异位表达显示高pErk水平和增强的细胞增殖。基于这些发现,我们建议FGFR4可能是肿瘤生长的驱动器,尤其是在通过基因改变高度表达或稳定并组成性激活时。这样,FGFR4为肿瘤中的进一步突变筛选提供了选择,并且是具有治疗潜力的有吸引力的癌症靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号